Tests royal jelly and propolis supplements in people with coronary artery disease
Tests a propolis and royal jelly supplement against placebo in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.
Key facts
- Where
- Niterói, BrazilSee the site
Where in Brazil
- Denise mafraNiterói, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidade Federal Fluminense
- Trial code
- NCT07596992
- Record updated
- 19 May 2026
- Original description
The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.Read full original descriptionShow less
Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.
The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.
Inclusion: Both sexes; Over 18 years of age; Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load); Participants who are asymptomatic or have angina limited to functional class III will be considered; Patients who have already undergone coronary revascularization and angioplasty may participate; the last acute coronary event must have occurred more than one year ago.
Exclusion: Unstable Coronary Artery Disease; Unstable angina; Individuals with autoimmune diseases; Advanced chronic kidney disease (creatinine clearance < 30 ml/min/1.73 m²); Pre-operative coronary artery bypass grafting or awaiting elective angioplasty; NYHA functional class III or higher.